Latest advances in diagnosing and predicting DILI: what was new in 2017?

References

• Shoda L, Battista C, Siler S, et al. Mechanistic modelling of drug-induced liver injury: investigating the role of innate immune responses. Gene Regul Syst Bio. 2017;11:1–22.
   Web of Science ®Google Scholar
• Yang K, Battista C, Woodhead J, et al. Systems Pharmacology modeling of drug-induced hyperbilirubinemia: differentiating hepatotoxicity and inhibition of enzymes/transporters. Clin Pharmacol Ther. 2017;101(4):501–509.
   PubMed Web of Science ®Google Scholar
• Church RJ, Watkins PB. In silico modeling to optimize interpretation of liver safety biomarkers in clinical trials. Exp Biol Med (Maywood). 2018;243(3):300–307.
   PubMed Web of Science ®Google Scholar
• Goda K, Kobayashi A, Takahashi A. Evaluation of the potential risk of drugs to induce hepatotoxicity in human-relationships between hepatic steatosis observed in non-clinical toxicity study and hepatotoxicity in humans. Int J Mol Sci. 2017;18(4):810.
   Web of Science ®Google Scholar
• McEuen K, Borlak J, Tong W, et al. Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury. Int J Mol Sci. 2017;18:7.
   Web of Science ®Google Scholar
• Battista C, Howell BA, Siler SQ, et al. An introduction to DILIsym®. In: Chen M, Will Y, editors. Drug-Induced liver toxicity. New York (NY): Humana Press; 2018. p. p 101–121.
   Google Scholar
• Kullak-Ublick GA, Andrade RJ, Merz M, et al. Drug-induced liver injury: recent advances in diagnosis and risk assessment. Gut. 2017;66:1154–1164.
   PubMed Web of Science ®Google Scholar
• Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8:186–195.
   PubMed Web of Science ®Google Scholar
• Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568–579.
   PubMed Web of Science ®Google Scholar
• Clare K, Miller M, Dillon J. Genetic factors influencing drug-induced liver injury: do they have a role in prevention and diagnosis? Curr Hepatology Rep. 2017;16:258–264.
   PubMedGoogle Scholar
• Petros Z, Makonnen E, Aklillu E. Genome-wide association studies for idiosyncratic drug-induced hepatotoxicity: looking back-looking forward to next-generation innovation. OMICS. 2017;21(3):123–131.
   PubMed Web of Science ®Google Scholar
• Ocete-Hita E, Salmerón-Fernández M, Urrutia-Maldonado E, et al. Analysis of immunogenetic factors in idiosyncratic drug-induced liver injury in the pediatric population. J Pediatr Gastroenterol Nutr. 2017;64(5):742–747.
   PubMed Web of Science ®Google Scholar
• Nicoletti P, Aithal G, Bjornsson E, et al. Association of liver injury from specific drugs or groups of drugs with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology. 2017;152(5):1078–1089.
   PubMed Web of Science ®Google Scholar
• Urban T, Nicoletti P, Chalasani N. Minocycline hepatotoxicity: clinical characterization and identification of HLA-B*35:02 as a risk factor. J Hepatol. 2017;67(1):137–144.
   PubMed Web of Science ®Google Scholar
• Lee W, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Safety. 2005;28(4):351–370.
   PubMed Web of Science ®Google Scholar
• Lundgren H, Martinsson K, Cederbrant K, et al. HLA-DR7 and HLA-DQ2: transgenic mouse strains tested as a model system for ximelagatran hepatotoxicity. PLoS One. 2017;12(9):1–16.
   Web of Science ®Google Scholar
• Hiraswawa M, Hagihara K, Abe K, et al. In Silico and in vitro analysis of interaction between ximelagatran and Human Leukocyte Antigen (HLA)-DRB1*07:01. Int J Mol Sci. 2017;18(4):694.
   Web of Science ®Google Scholar
• Petros Z, Kishikawa J, Makonnen E, et al. HLA-B*57 Allele is associated with concomitant anti-tuberculosis and antiretroviral drugs induced liver toxicity in Ethiopians. Front Pharmacol. 2017;8:90.
   PubMed Web of Science ®Google Scholar
• Liss G, Rattan S, Lewis J. Predicting and preventing acute drug-induced liver injury: what’s new in 2010. Expert Opin Drug Metab Toxicol. 2010;9:1–15.
   Google Scholar
• Zimmerman H. Hepatotoxicity. The adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins; 1999.
   Google Scholar
• Hawkins M, Lewis J. Latest advances in predicting DILI in human subjects: focus on biomarkers. Expert Opin Drug Metab Toxicol. 2012;8(12):1521–1530.
   PubMed Web of Science ®Google Scholar
• Singla R, Sharma S, Mohan A. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity. Indian J Med Res. 2010;132:81–86.
   PubMed Web of Science ®Google Scholar
• Suzuki A, Barnhart H, Gu J. Associations of gender and a proxy of female menopausal status with histological features of drug-induced liver injury. Liver Int. 2017;37(11):1723–1730.
   PubMed Web of Science ®Google Scholar
• Lo Re V 3rd, Zeldow B, Mj K, et al. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiol Drug Saf. 2017;26(10):1172–1181.
   PubMed Web of Science ®Google Scholar
• Byrne DD, Tate JP, Forde KA, et al. Risk of acute liver injury after statin initiation by human immunodeficiency virus and chronic Hepatitis C virus infection status. Clin Infect Dis. 2017;65(9):1542–1550.
   PubMed Web of Science ®Google Scholar
• Kim RG, Loomba R, Prokop LJ, et al. Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis. Clin Gastro Hepatol. 2017;15:1521–1530.
   PubMed Web of Science ®Google Scholar
• Kamal S, Khan MA, Seth A, et al. Decompensation and mortality in chronic liver disease: a systematic review and meta-analysis. Am J Gastro. 2017;112:1495–1505.
   PubMed Web of Science ®Google Scholar
• Chamorro JG, Castagnino JP, Aidar O, et al. Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2017;27(10):363–371.
   PubMed Web of Science ®Google Scholar
• Sun Q, Liu HP, Zheng RJ, et al. Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and susceptibility to Anti-Tuberculosis Drug-induced hepatotoxicity: a chinese population-based prospective case-control study. Clin Drug Investig. 2017;37(12):1125–1136.
   PubMed Web of Science ®Google Scholar
• Hakamata J, Hashiguchi M, Kaneko Y, et al. Risk factors for abnormal hepatic enzyme elevation by methotrexate treatment in patients with rheumatoid arthritis: a hospital based-cohort study. Mod Rheumatol. 2018.
   PubMed Web of Science ®Google Scholar
• Kotsampasakou E, Montanari F, Ecker G. Predicting drug-induced liver injury: the importance of data curation. Toxicology. 2017;389:139–145.
   PubMed Web of Science ®Google Scholar
• Maiuri A, Wassink B, Turkus J. Synergistic cytotoxicity from drugs and cytokines in vitro as an approach to classify drugs according to their potential to cause idiosyncratic hepatotoxicity: a proof of concept study. J Pharmacol Exp Ther. 2017;362(3):459–473.
   PubMed Web of Science ®Google Scholar
• Rueda-Zarate H, Imaz-Rosshandler I, Cardenas-Ovando R, et al. A computational toxicogenomics approach identifies a list of highly hepatotoxic compounds from a large microarray database. PLoS One. 2017;12(4):e0126284.
   Web of Science ®Google Scholar
• Longo DM, Yang Y, Watkins PB, et al. Elucidating differences in the hepatotoxic potential of tolcapone and entacapone with DILIsym(®), a mechanistic model of drug-induced liver injury. CPT Pharmacometrics Syst Pharmacol. 2016;5(1):31–39.
   PubMedGoogle Scholar
• Shoda LK, Woodhead JL, Siler SQ, et al. Linking physiology to toxicity using DILIsym®, a mehanistic mathematical model of drug-induced liver injury. Biopharm Drug Dispos. 2014;35(1):33–49.
   PubMed Web of Science ®Google Scholar
• Woodhead J, Brock W, Roth S, et al. Application of mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicological Sci. 2016;155(1):61–74.
   PubMed Web of Science ®Google Scholar
• Longo DM, Generaux GT, Howell BA, et al. Refining liver safety risk assessment: application of mechanistic modeling and serum biomarkers to cimaglermin alfa (GGF2) clinical trials. Clin Pharmacol Ther. 2017;102(6):961–969.
   PubMed Web of Science ®Google Scholar
• Battista C, Yang K, Mettetal JT, et al. Mechanistic modeling with DILIsym® predicts species differences in CKA via multiple hepatotoxic mechanisms. J Pharacokinet Pharmacodyn. 2016;43:15.
   Web of Science ®Google Scholar
• Howell BA, Siler SQ, Watkins PB. Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice. Toxicol Lett. 2014;226(2):163–172.
   PubMed Web of Science ®Google Scholar
• Howell BA, Siler SQ, Shoda LK, et al. A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacometrics Syst Pharmacol. 2014;3:98.
   Google Scholar
• Yang K, Woodhead JL, Watkins PB, et al. Systems pharmacology modeling predicts delayed presentation and species differences in bile acid-mediated troglitazone hepatotoxicity. Clin Pharmacol Ther. 2014;589–598.
   PubMed Web of Science ®Google Scholar
• Woodhead J, Watkins P, Howell B. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet. 2017;32(1):40–45.
   PubMed Web of Science ®Google Scholar
• Jh C, Plise E, Cheong J, et al. Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia. Mol Pharm. 2013;10:3067–3075.
   PubMedGoogle Scholar
• Meeting of the Antimicrobial Drugs Advisory Committee (AMDAC) [Internet]. FDA briefing document solithromycin oral capsule and injection. 2016. [cited 2018 Jul 13]. Available from: http://www.fda.gov
   Google Scholar
• Hong H, Thakkar S, Chen M, et al. Development of decision forest models for prediction of drug-induced liver injury in humans using a large set of FDA-approved drugs. Sci Rep. 2017;7(1):17311.
   PubMedGoogle Scholar
• Robles-Díaz M, Medina-Caliz I, Stephens C, et al. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267.
   PubMed Web of Science ®Google Scholar
• Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017;37(11):1582–1590.
   PubMed Web of Science ®Google Scholar
• Lin H, Ewing LE, Koturbash I, et al. MicroRNAs as biomarkers for liver injury: current knowledge, challenges and future prospects. Food Chem Toxicol. 2017;110:229–239.
   PubMed Web of Science ®Google Scholar
• Araújo AM, Carvalho M, Carvalho F, et al. Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI). Crit Rev Toxicol. 2017;47(8):633–649.
   PubMed Web of Science ®Google Scholar
• Sanjay S, Girish C. Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury. Eur J Clin Pharmacol. 2017;73(4):399–407.
   PubMed Web of Science ®Google Scholar
• Howell LS, Ireland L, Park BK, et al. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury. Expert Rev Mol Diagn. 2018;18(1):47–54.
   PubMed Web of Science ®Google Scholar
• Rissin D, Lopez-Longarela B, Pernagallo S. Poymerase-free measurement of microRNA-122 with single base specificity using single molecule arrays: detection of drug-induced liver injury. PLoS ONe. 2017;12(7):e0179669.
   PubMed Web of Science ®Google Scholar
• Vliegenthart A, Berends C, Potter C, et al. microRNA-122 can be measured in capillary blood which facilitates point-of-care testing for drug-induced liver injury. Br J Clin Pharmacol. 2017;83(9):2027–2033.
   PubMed Web of Science ®Google Scholar
• Lee J, Ji SC, Kim B, et al. Exploration of biomarkers for Amoxicillin/Clavulanate-induced liver injury: multi-omics approaches. Clin Transl Sci. 2017;10(3):163–171.
   PubMed Web of Science ®Google Scholar
• Russo MW, Steuerwald N, Norton HJ, et al. Profiles of miRNAs in serum in severe acute drug induced liver injury and their prognostic significance. Liver Int. 2017;37(5):757–764.
   PubMed Web of Science ®Google Scholar
• Lauschke V. Dysregulation of miR-223 constitutes a promising biomarker that informs about clinical outcomes of acute liver failure. Clin Sci (Lond). 2017;131(15):2059–2062.
   PubMed Web of Science ®Google Scholar
• Fang C, Li XP, Gong WJ, et al. Age-related common miRNA polymorphism associated with severe toxicity in lung cancer patients treated with platinum-based chemotherapy. Clin Exp Pharmacol Physiol. 2017;44(Suppl 1):21–29.
   PubMedGoogle Scholar
• Krauskopf J, De Kok TM, Schomaker SJ, et al. Serum microRNA signatures as “liquid biopsies” for interrogating hepatotoxic mechanisms and liver pathogenesis in human. PLoS One. 2017;12(5):e0177928.
   PubMed Web of Science ®Google Scholar
• Yamaura Y, Tatsumi N, Takagi S, et al. Serum microRNA profiles in patients with chronic hepatitis B, chronic hepatitis C, primary biliary cirrhosis, autoimmune hepatitis, nonalcoholic steatohepatitis, or drug-induced liver injury. Clin Biochem. 2017;50(18):1034–1039.
   PubMed Web of Science ®Google Scholar
• Hong M, Li S, Tan H, et al. A network-based pharmacology study of the herb-induced liver injury potential of traditional hepatoprotective chinese herbal medicines. Molecules. 2017;22(4):632.
   Web of Science ®Google Scholar
• Yang R, Yang F, Huang Z, et al. Serum microRNA-122-3p, microRNA-194-5p and microRNA-5099 are potential toxicological biomarkers for the hepatotoxicity induced by Airpotato yam. Toxicol Lett. 2017;280:125–132.
   PubMed Web of Science ®Google Scholar
• Huang Z, Chen M, Zhang J, et al. Integrative analysis of hepatic microRNA and mRNA to identify potential biological pathways associated with monocrotaline-induced liver injury in mice. Toxicol Appl Pharmacol. 2017;333:35–42.
   PubMed Web of Science ®Google Scholar
• Yu D, Wu L, Gill P, et al. Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018;92(2):845–858.
   PubMed Web of Science ®Google Scholar
• Kakisaka K, Yoshida Y, Suzuki Y, et al. Serum markers for mitochondrial dysfunction and cell death are possible predictive indicators for drug-induced liver injury by direct acting antivirals. Hepatol Res. 2018;48(1):78–86.
   PubMed Web of Science ®Google Scholar
• Cho Y, Im E, Moon P, et al. Increased liver-specific proteins in circulating extracellular vesicles as potential biomarkers for drug- and alcohol-induced liver injury. PLoS One. 2017;12(2):e0172463.
   PubMed Web of Science ®Google Scholar
• Cho Y, Kim S, Lee B, et al. Circulating plasma and exosomal microRNAs as Indicators of drug-induced organ injury in rodent models. Biomol Ther (Seoul). 2017;25(4):367–373.
   PubMed Web of Science ®Google Scholar
• Schnackenberg LK, Sun J, Bhattacharyya S, et al. Metabolomics analysis of urine samples from children after acetaminophen overdose. Metabolites. 2017;7(3):46.
   Web of Science ®Google Scholar
• Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology. 2018. 2018 7 13. DOI:10.1002/hep.29802.
   Google Scholar
• Peta V, Tse C, Perazzo H, et al. Drug induced liver injury- groupe hospitalier Pitié-Salpêtrière.; drug induced liver group of the injury safer and faster evidence-based translation consortium. Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. PLoS One. 2017;12(12):e0189436.
   PubMed Web of Science ®Google Scholar
• Mikus M, Drobin K, Gry M, et al. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver Int. 2017;37(1):132–140.
   PubMed Web of Science ®Google Scholar
• Chan R, Benet L. Evaluation of DILI predictive hypotheses in early drug development. Chem Res Toxicol. 2017;30(4):1017–1029.
   PubMed Web of Science ®Google Scholar
• Cheng D, Xu W, Yuan L. Investigation of drug-induced hepatotoxicity and its remediation pathway with reaction-based fluorescent probes. Anal Chem. 2017;89(14):7693–7700.
   PubMed Web of Science ®Google Scholar
• Li Y, Xie X, Yang X, et al. Two-photon fluorescent probe for revealing drug-induced hepatotoxicity via mapping fluctuation of peroxynitrite. Chem Sci. 2017;8(5):4006–4011.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jin Z, Hu X. Efficient two-photon fluorescent probe for glutathione S-transferase detection and imaging in drug-induced liver injury sample. Anal Chem. 2017;89(15):8097–8103.
   PubMed Web of Science ®Google Scholar
• Vasquez K, Peterson J. Early detection of acute drug-induced liver injury in mice by non-invasive NIR fluorescent imaging. J Pharmacol Exp Ther. 2017;361(1):87–89.
   PubMedGoogle Scholar
• Nguyen X, Kislyuk S, Pham D. Cell imaging counting as a novel ex vivo approach for investigating drug-induced hepatotoxicity in zebrafish larvae. Int J Mol Sci. 2017;18(2):356.
   Web of Science ®Google Scholar
• Brillant N, Elmasry M, Burton NC, et al. Dynamic and accurate assessment of acetaminophen-induced hepatotoxicity by integrated photoacoustic imaging and mechanistic biomarkers in vivo. Toxicol Appl Pharmacol. 2017;332:64–74.
   PubMed Web of Science ®Google Scholar
• Teschke R, Schulze J, Eickhoff A, et al. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18(4):803.
   Web of Science ®Google Scholar